The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
The AHA today responded to a Centers for Medicare & Medicaid Services request for information by offering solutions for improving maternal and child health…
Headline
AHA yesterday urged the Federal Communications Commission to grant expedited approval to its request that the agency extend the COVID-19 Telehealth Program to…
Headline
Health experts agree that telemedicine’s ability to bring virtual expertise to bedsides everywhere is a vital tool for fighting COVID-19. On this AHA podcast,…
Chairperson's File
As our nation’s caregivers remain courageously entrenched in the battle against COVID-19, AHA is working to ensure that telehealth is realizing its potential…
Headline
The AHA urged HHS and CMS to consider taking additional actions that would expand the ability of hospitals and health systems to use telehealth in response to…
Headline
The Centers for Medicare & Medicaid Services yesterday released a substantial number of new waivers related to COVID-19. The waivers apply nationwide and…